<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77655">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02094573</url>
  </required_header>
  <id_info>
    <org_study_id>AP26113-13-201</org_study_id>
    <nct_id>NCT02094573</nct_id>
  </id_info>
  <brief_title>A Phase 2, Multicenter, Randomized Study of AP26113</brief_title>
  <acronym>ALTA</acronym>
  <official_title>A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ariad Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of two different dosing
      regimens of AP26113 in patients with anaplastic lymphoma kinase (ALK)-positive locally
      advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on
      therapy with crizotinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, phase 2, open-label, multicenter, international study to evaluate the
      efficacy and safety of two different dosing regimens of AP26113 in patients with
      ALK-positive, locally advanced or metastatic NSCLC who have previously been treated with
      crizotinib.

      The primary objective of the study is to determine the efficacy of AP26113, as evidenced by
      confirmed objective response rate (ORR), as assessed by the investigator, per Response
      Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Two dosing regimens will be
      tested. The secondary objectives of the study (for each dosing regimen) include confirmed
      ORR, as assessed by a central independent review committee (IRC), per RECIST v1.1; CNS
      response (ORR and progression free survival [PFS]), per RECIST v1.1, in patients with active
      brain metastases); time to/duration of response; time on treatment; disease control rate,
      per RECIST v.1.1; PFS; overall survival (OS); safety and tolerability; population
      pharmacokinetics (PK); and patient-reported symptoms of lung cancer and health-related
      quality of life (HRQoL). Exploratory objectives (for each dosing regimen) include
      correlation of AP26113 exposure with both efficacy and safety and correlation of tumor and
      plasma biomarkers with AP26113 efficacy and safety. It is estimated that accrual will be
      completed within 18 months; the total estimated duration of the study is 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Confirmed ≥4 weeks after initial response. Until discontinuation or the end of the study.</time_frame>
    <description>Defined as the composite of complete response (CR) and partial response (PR). To assess objective response rate in the intention to treat population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Until the end of the study or death.</time_frame>
    <description>Defined as the interval between enrollment and death due to any cause, censored at the last contact date. To assess OS in the intention to treat population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Until the end of the study or disease progression or death due to any cause.</time_frame>
    <description>Defined as the duration of time from start of study drug administration to time of objective disease progression or death due to any cause, whichever may come first. To assess PFS in the intention to treat population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQoL)</measure>
    <time_frame>Until 30 days after the last dose of study treatment.</time_frame>
    <description>Defined as the perceived quality of the patient's life, which includes self-reported multidimensional measures of physical and mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Until the end of the treatment.</time_frame>
    <description>Measured by routine physical and laboratory evaluations, ECG, and adverse event (AE) monitoring. To evaluate the safety and tolerability of AP26113 in the intention to treat population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of steady-state plasma concentration.</measure>
    <time_frame>At designated time points in dosing Cycles 2, 3, 4 and 5.</time_frame>
    <description>PK samples will be taken to assess limited elements of PK in the intention to treat population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Advanced Malignancies</condition>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP26113 will be administered to eligible patients with locally advanced or metastatic ALK+ NSCLC at a dose of 90 mg QD, continuously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP26113 will be administered to eligible patients with locally advanced or metastatic ALK+ NSCLC at a dose of 90 mg QD for 7 days, then 180 mg QD, continuously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP26113</intervention_name>
    <description>90 mg tablet, taken orally once daily,continuously in a 28-day cycle</description>
    <arm_group_label>Arm A:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP26113</intervention_name>
    <description>90 mg tablet, taken orally once daily for a 7 days, then a 180 mg tablet taken orally once daily, continuously in a 28-day cycle</description>
    <arm_group_label>Arm B:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have histologically or cytologically confirmed locally advanced or metastatic NSCLC
             that is ALK+.

          2. Must meet one of the following two criteria:

               1. Have documented ALK rearrangement by a positive result from the Vysis® ALK
                  Break-Apart fluorescence in situ hybridization (FISH) Probe Kit; or

               2. Have documented ALK positivity by a different test and tissue available for the
                  Vysis® FISH test. Tissue should be derived preferably from a biopsy taken after
                  progression with crizotinib. If such a sample is not available, testing may be
                  performed with archived tumor tissue.

          3. Had progressive disease while on crizotinib, as assessed by the investigator or
             treating physician.

          4. Have at least 1 measurable lesion per RECIST v1.1. Note: Previously irradiated
             lesions may not be used for target lesions, unless there is unambiguous radiological
             progression after radiotherapy. Brain lesions may not be used as target lesions if
             they were: 1) previously treated with whole brain radiation therapy (WBRT) within 3
             months, or 2) previously treated by stereotactic radiosurgery (SRS) or surgical
             resection.

          5. Recovered from toxicities related to prior anticancer therapy to National Cancer
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v4.0) grade
             ≤2.

          6. Are a male or female patient ≥18 years old.

          7. Have a life expectancy ≥3 months.

          8. Have adequate organ and hematologic function, as determined by:

               1. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x upper
                  limit of normal (ULN; ≤5 x ULN is acceptable if liver metastases are present)

               2. Total serum bilirubin ≤1.5 x ULN (&lt;3.0 x ULN for patients with Gilbert syndrome)

               3. Serum creatinine ≤1.5 x ULN

               4. Serum lipase/amylase ≤1.5 x ULN

               5. Absolute neutrophil count (ANC) ≥1500/µL

               6. Platelets ≥75000/µL

               7. Hemoglobin ≥10 g/dL

          9. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

         10. Have normal QT interval on screening electrocardiogram (ECG) evaluation, defined as
             QT interval corrected (Fridericia) (QTcF) of ≤450 ms in males or ≤470 ms in females.

         11. For female patients of childbearing potential, a negative pregnancy test must be
             documented prior to enrollment.

         12. Female and male patients who are fertile must agree to use a highly effective form of
             contraception with their sexual partners throughout study participation.

         13. Must provide a signed and dated informed consent indicating that the patient has been
             informed of all pertinent aspects of the study, including the potential risks, and is
             willingly participating.

         14. Have the willingness and ability to comply with scheduled visits and study
             procedures.

        Exclusion Criteria:

          1. Received any prior ALK-targeted TKI other than crizotinib.

          2. Received crizotinib within 3 days of the first dose of AP26113 (Day 1, Cycle 1).

          3. Received cytotoxic chemotherapy, investigational agents, or radiation within 14 days,
             except SRS or stereotactic body radiosurgery.

          4. Received monoclonal antibodies or had major surgery within 30 days of the first dose
             of AP26113 (Day 1, Cycle 1).

          5. Have been diagnosed with another primary malignancy within the past 3 years (except
             for adequately treated non-melanoma skin cancer, cervical cancer in situ, or prostate
             cancer, which are allowed within 3 years).

          6. Have symptomatic CNS metastases that are neurologically unstable or require an
             increasing dose of corticosteroids.

          7. Have current spinal cord compression.

          8. Have significant, uncontrolled, or active cardiovascular disease, specifically
             including, but not restricted to:

               1. Myocardial infarction (MI) within 6 months prior to the first dose of AP26113

               2. Unstable angina within 6 months prior to first dose

               3. Congestive heart failure (CHF) within 6 months prior to first dose

               4. History of clinically significant (as determined by the treating physician)
                  atrial arrhythmia

               5. Any history of ventricular arrhythmia

               6. Cerebrovascular accident or transient ischemic attack within 6 months prior to
                  first dose

          9. Have a history or the presence of pulmonary interstitial disease or drug-related
             pneumonitis.

         10. Have an ongoing or active infection. The requirement for intravenous (IV) antibiotics
             is considered active infection.

         11. Have a known history of human immunodeficiency virus (HIV). Testing is not required
             in the absence of history.

         12. Have a history of or active significant gastrointestinal (GI) bleeding within 3
             months of the first dose of AP26113.

         13. Have a known or suspected hypersensitivity to AP26113 or its excipients.

         14. Have malabsorption syndrome or other GI illness that could affect oral absorption of
             the study drug.

         15. Have any condition or illness that, in the opinion of the investigator, would
             compromise patient safety or interfere with evaluation of the drug study.

         16. Be pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic Arizona (Site 229)</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope (Site 009)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moores Cancer Center University of California, San Diego (Site 099)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center, Chao Family Comprehensive Cancer Center (Site 210)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente (Site 208)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center (Site 015)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center (Site 033)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of South Florida (Site 204)</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center (Site 017)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University (Site 058)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center (Site 001)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (Site 044)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Health Care; N.C. Cancer Hospital Infusion/Inpatient Pharmacy (CHIP) (Site 032)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute-Concord/Clinical Trials (Site 056)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center (Site 205)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania, Perelman Center for Advanced Medicine (Site 013)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center (Site 005)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute (Site 211)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne (Site997)</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula &amp; South Eastern Haematology Group (Site 994)</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health, Austin Hospital ((Site 999)</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Cancer Centre, Gosford Hospital (Site 402)</name>
      <address>
        <city>Gosford</city>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The St George Hospital, Cancer Care Center (Site 403)</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Priness Alexandra Hospital, Cancer Services (Site 942)</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Johanns-Spital, Universitatsklinik fur Pneumologie/Lungenheilkunde (Site 627)</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMZ Baumgartner Hohe Otto Wagner Spital, Onkologische Ambulanz+Tagesklinik (Site 612)</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.-Hartziekenhuis Roeselare-Menen vzw (Site 617)</name>
      <address>
        <city>Roeselare</city>
        <state>West-Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre (Site 131)</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital (Site 614)</name>
      <address>
        <city>DK 2730 Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital (Site 615)</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse Service de Pneumologie (Site 568)</name>
      <address>
        <city>Caen Cedex 05</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse, Service de Pneumologie (Site 568)</name>
      <address>
        <city>Caen Cedex 05</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Caen, Service de pneumologie (Site 611)</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - hospital Michallon (Site 569)</name>
      <address>
        <city>Grenoble cedex 9</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard, Departement d'oncologie Medicale (Site 746)</name>
      <address>
        <city>Lyon cedex 08</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne (Site 570)</name>
      <address>
        <city>Nice Cedex 2</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin, Service d'oncolgie Medicale du Pr Goldwasser (Site 616)</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers (Site 605)</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen, Hospital Charles Nicolle, Service de Pneumologie (Site 585)</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Civil (Site 610)</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>6709</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Lungenklinik Berlin (Site 588)</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha Marie Halle (Site 572)</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik-Heidelberg gGmbH, Innere Medizin - Onkologie (Site 586)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer, Zentrum fur Pneumologie und Thoraxchirurgie (Site 620)</name>
      <address>
        <city>Hemer</city>
        <zip>58656</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel GmbH, Klinik fur Onkologie und Hamatologie (Site 573)</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Koln gGmbH, Lungenkrebszentrum Koln-Merheim (Site 626)</name>
      <address>
        <city>Koln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU - Klinikum der Universitat Munchen, Campus Innenstadt, Medizinische Klinik V, Pneumologie (Site 609)</name>
      <address>
        <city>Munchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital, Department of Clinical Oncology (Site 986)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital, Division of Respiratory and Critical Care Medicine (Site 973)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital (Site 987)</name>
      <address>
        <city>Kowloon</city>
        <zip>150001</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital, Department of Clinical Oncology (Site 987)</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.O.C. Oncologia Medica A, Centro di Riferimento Oncologico, I.R.C.C.S., Istituto Nazionale Tumori (Site 624)</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Oncologia Medica, Ospedale A. Perrino, Presidio Ospedaliero Di Summa - Perrino, Azienda Sanitaria Locale di Brindisi (Site 629)</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Medica Azienda USL 6 Livorno, Presidio Ospedaliero di Livorno (Site 576)</name>
      <address>
        <city>Livorno</city>
        <zip>57124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Medica, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)_IRCCS (Site 575)</name>
      <address>
        <city>Meldola (FC)</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica Ospedale San Raffaele, Istituto di Ricovero e Cura a Carattere Scientifico (Site 578)</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Oncologia Toracica, Istituto Europeo di Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico (Site608)</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Oncologia Medica, Azienda Ospedaliero-Universitaria Maggiore della Carita di Novara (Site 574)</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa Oncologia Medica Azienda Ospedaliero-Universitaria di Parma (Site 607)</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica A, IRCCS, Istituti Fisioterapici Ospitalieri (Site 632)</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Oncologia, Azienda Ospedaliera Sant'Andrea (Site 631)</name>
      <address>
        <city>Rome</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center (Site 916)</name>
      <address>
        <city>Goyang-si</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital (Site 915)</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System (Site 913)</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital (Site 938)</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center (Site 917)</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center (Site 948)</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (Site 579)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (Site 581)</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+ (Site 580)</name>
      <address>
        <city>Masstricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF, Radiumhospitalet (Site 630)</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore, Depart of Medical Oncology (Site 989)</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OncoCare Cancer Centre (Site 988)</name>
      <address>
        <city>Singapore</city>
        <zip>258499</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera (Site 554)</name>
      <address>
        <city>A Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro-Majahahonda (Site 634)</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante (Site 591)</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Dexeus, Servicio de Oncologia Medica (Site 590)</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de la Vall d'Hebron Servicio de Oncologia Medica (Site 503)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre (Site 537)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre Oncologia Medica (Site 537)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz (Site 582)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer (Site 625)</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio (Site 592)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia (Site 589)</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset (Site 758)</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital - Universitatsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust (Site 721)</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital (Site 628)</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust (Site 725)</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Non-small cell lung carcinoma</keyword>
  <keyword>Epithelial lung cancer</keyword>
  <keyword>Squamous cell carcinoma</keyword>
  <keyword>Large cell carcinoma</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Anaplastic lymphoma kinase (ALK)</keyword>
  <keyword>Advanced Malignancies</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Advanced Cancers</keyword>
  <keyword>AP26113</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
